BioSpace News Archive

MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug Application (IND) to evaluate the safety, efficacy, pharmacodynamics and pharmacokinetics of oral TNF-α inhibitor MYMD-1® in patients with active rheumatoid arthritis (RA).

Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc., announced that it has entered into a Royalty Purchase Agreement for a portion of Radius’s royalty and commercial milestone stream in elacestrant, the first and only treatment approved for ER+/HER2-, ESR1- mutated advanced or metastatic breast cancer, with DRI Healthcare Acquisitions LP.

Ketabon, a joint venture between HMNC Brain Health and Develco Pharma, announced today top-line results from its Phase 2 KET01-02 Ketabon study with lead asset KET01.

CNS Pharmaceuticals, Inc. today announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Company’s novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier.

Arcturus Therapeutics Holdings Inc. announced that ARCALIS Co., Ltd., its manufacturing joint venture in Japan to support the production of mRNA vaccines and therapeutics, has been awarded $115 million in two separate grants from the Japanese government.

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Versanis Bio.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that on August 10, 2023 it received a final cost award from the International Center for Dispute Resolution (ICDR), International Abritration Tribunal, in the Matter of Arbitration between Elmar Burchardt vs Hemostemix Inc.

Advanced Infusion Care, a division of AIS Healthcare, announced the opening of a new pharmacy location in Cockeysville, Maryland.

International Isotopes Inc. announces its financial results for the three- and six-month periods ended June 30, 2023.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the submission of a De Novo request to the U.S. Food and Drug Administration (FDA) for the TAEUS system.